Immunovant, Inc. (IMVT)
36.24
-0.42
(-1.13%)
USD |
NASDAQ |
Sep 16, 15:34
Immunovant Total Assets (Quarterly) : 852.49M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 852.49M |
| March 31, 2026 | 957.57M |
| December 31, 2025 | 1.052B |
| September 30, 2025 | 582.96M |
| June 30, 2025 | 661.44M |
| March 31, 2025 | 777.32M |
| December 31, 2024 | 420.93M |
| September 30, 2024 | 515.71M |
| June 30, 2024 | 589.68M |
| March 31, 2024 | 666.71M |
| December 31, 2023 | 711.45M |
| September 30, 2023 | 292.07M |
| June 30, 2023 | 351.22M |
| March 31, 2023 | 405.84M |
| Date | Value |
|---|---|
| December 31, 2022 | 456.24M |
| September 30, 2022 | 428.15M |
| June 30, 2022 | 458.66M |
| March 31, 2022 | 515.56M |
| December 31, 2021 | 543.18M |
| September 30, 2021 | 566.73M |
| June 30, 2021 | 388.03M |
| March 31, 2021 | 412.49M |
| December 31, 2020 | 433.03M |
| September 30, 2020 | 453.90M |
| June 30, 2020 | 290.29M |
| March 31, 2020 | 109.39M |
| December 31, 2019 | 126.62M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Moderna, Inc. | 10.96B |
| Altimmune, Inc. | 527.21M |
| TG Therapeutics, Inc. | 1.640B |
| Dianthus Therapeutics, Inc. | 1.213B |
| First Tracks Biotherapeutics, Inc. | 183.14M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 117.10M |
| Shareholders Equity (Quarterly) | 735.39M |
| Current Ratio | 7.269 |
| Net Debt Paydown Yield | 0.00% |